Blood test may predict rapid kidney decline in diabetes

NCT ID NCT04960514

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether a blood-based test called KidneyIntelX can help doctors better manage type 2 diabetes patients with early to moderate chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this test leads to more patients hitting treatment targets, like blood pressure and blood sugar control, and receiving protective medications. The goal is to see if this tool improves clinical decisions and ultimately slows kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KidneyIntelX, a blood-based diagnostic test that predicts the risk of rapid kidney function decline
What this could lead to
If effective, this test could help doctors identify high-risk patients earlier and tailor treatments to slow kidney disease progression.
What could go wrong
The trial is large but focuses on whether the test changes doctor decisions, not on long-term patient outcomes. The test may not lead to meaningful improvements in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist - Family Medicine - Piedmont Plaza

    Winston-Salem, North Carolina, 27104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.